Turk, Anita A <br/><br/>
PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.  [electronic resource] 

 -  Cancer  06 2018 
 - 2498-2506 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Review 
<br/><br/><label>ISSN: </label>1097-0142 
<br/><br/><label>Standard No.: </label>10.1002/cncr.31307  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents, Immunological--pharmacology<br/>Antineoplastic Combined Chemotherapy Protocols--pharmacology<br/>BRCA1 Protein--genetics<br/>BRCA2 Protein--genetics<br/>Breast Neoplasms--drug therapy<br/>Cell Survival--drug effects<br/>Clinical Trials as Topic<br/>DNA Repair--drug effects<br/>Drug Resistance, Neoplasm--drug effects<br/>Female<br/>Humans<br/>Molecular Targeted Therapy--methods<br/>Patient Selection<br/>Poly(ADP-ribose) Polymerase Inhibitors--pharmacology<br/>Poly(ADP-ribose) Polymerases--metabolism<br/>Synthetic Lethal Mutations<br/>Treatment Outcome